Published in Dev Cell on November 03, 2016
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem (1999) 10.14
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol (2005) 6.74
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res (2010) 3.71
The complexity of p53 stabilization and activation. Cell Death Differ (2006) 3.61
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A (2010) 3.18
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science (2003) 2.46
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell (2013) 2.32
Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol (1994) 2.32
Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J (1996) 2.31
Hippo pathway activity influences liver cell fate. Cell (2014) 2.24
Rac1 GTPase: a "Rac" of all trades. Cell Mol Life Sci (2009) 2.19
Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16
p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem (2001) 2.05
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol (2005) 1.86
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res (2007) 1.71
The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev (1997) 1.67
Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res (2013) 1.62
Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene (2004) 1.61
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res (2008) 1.55
Regulation of mTORC1 by PI3K signaling. Trends Cell Biol (2015) 1.54
A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat Cell Biol (2015) 1.52
Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet (2003) 1.47
Current issues with acetaminophen hepatotoxicity--a clinically relevant model to test the efficacy of natural products. Life Sci (2011) 1.46
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal (2011) 1.41
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 1.38
YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene (2012) 1.36
Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene (2000) 1.33
YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol (2015) 1.29
The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal (2013) 1.25
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell (2014) 1.22
Molecular pathogenesis of malignant mesothelioma. Carcinogenesis (2013) 1.16
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis (2008) 1.11
Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development (2013) 1.00
Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet (2002) 0.97
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis. PLoS One (2013) 0.95
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat Commun (2013) 0.95
Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci (2012) 0.94
Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging. Cell Death Dis (2013) 0.92
Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A (2015) 0.88
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology (2009) 0.88
A role for the p53 pathway in the pathology of meningiomas with NF2 loss. J Neurooncol (2008) 0.88
Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol (2008) 0.87
Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors. Oncogene (2012) 0.86
The significance of immunohistochemical expression of merlin, Ki-67, and p53 in meningiomas. Appl Immunohistochem Mol Morphol (2014) 0.85
Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas. J Neurosurg (2014) 0.85
Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int J Oncol (2013) 0.84
Nf2-Yap signaling controls the expansion of DRG progenitors and glia during DRG development. Dev Biol (2014) 0.83
The senescent hepatocyte gene signature in chronic liver disease. Exp Gerontol (2014) 0.80
YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis. Cancer Res (2016) 0.76
P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas. Eur Arch Otorhinolaryngol (2014) 0.75